Failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100 point reduction) · induction of remission in Crohn's disease
Briakinumab probably leads to lower failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (Panaccione 2010) · induction of remission in Crohn's disease
Briakinumab showed no clear difference in adverse events (Panaccione 2010) compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (Panaccione 2010) · induction of remission in Crohn's disease
Briakinumab showed no clear difference in serious adverse events (Panaccione 2010) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · induction of remission in Crohn's disease
Briakinumab showed no clear difference in withdrawals due to adverse event** (Pannaccione 2010) compared with placebo (low certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · induction of remission in Crohn's disease
Ustekinumab leads to lower failure to induce clinical remission CDAI (≤ 150) compared with placebo (high certainty).
2 findings from 1 review
Induction of remission (CDAI <150), therapeutic response (VHI decrease >=25%) or clinical improvement · patients with Induction of remission or response in Crohn's disease
Sulfasalazine showed no clear difference in induction of remission (CDAI <150), therapeutic response (VHI… compared with placebo (low certainty).
1 finding from 1 review
Clinical remission or improvement · patients with Induction of remission or response in Crohn's disease
It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission or clinical improvement ‐ Asacol (3.2 g/day) compared with placebo (very low certainty).
2 findings from 1 review
Induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2 g/day) · patients with Induction of remission or response in Crohn's disease
It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2… compared with placebo (very low certainty).
1 finding from 1 review
Induction of remission (CDAI < or =150 with or without decrease of at least 60 points) · patients with Induction of remission or response in Crohn's disease
Delayed‐release mesalamine (3 ‐ 4.5 g/day) showed no clear difference in induction of remission (CDAI < or =150 with or without decrease of… compared with corticosteroids (moderate certainty).
5 findings from 1 review
RR 1.04 [0.79, 1.36]
3 studies · 178 participants
Moderate
RR 0.95 [0.49, 1.85]
1 study · 50 participants
Low
RR 1 [0.61, 1.64]
1 study · 50 participants
Moderate
Show 2 more findings
Induction of clinical remission (CDAI < or = 150) · patients with Induction of remission or response in Crohn's disease
Mesalamine (4 ‐ 4.5 g/day) may leads to lower induction of remission (CDAI < or = 150) ‐ Pentasa (4 g/day) compared with budesonide (low certainty).
2 findings from 1 review
Clinical remission or improvement · patients with Induction of remission or response in Crohn's disease
It is very uncertain whether mesalamine changes induction of remission (CDAI < 150) or clinical improvement ‐… compared with sulfasalazine (alone or (very low certainty).
2 findings from 1 review
Remission · patients with Induction of remission or response in Crohn's disease
Sulfasalazine showed no clear difference in induction of remission (CDAI <150) (Random Effects Model) compared with placebo (moderate certainty).
1 finding from 1 review
CDAI <150 at 24 weeks · patients with Induction of remission or response in Crohn's disease
Sulfasalazine probably leads to lower induction of remission (CDAI <150) compared with corticosteroids (moderate certainty).
1 finding from 1 review
Remission · patients with Induction of remission or response in Crohn's disease
Sulfasalazine probably leads to lower induction of remission compared with sulfasalazine and corticosteroids (moderate certainty).
1 finding from 1 review
Decrease in CDAI >=50, HBI >=2 or improvement/remission (as defined by Tvede et al) · patients with Induction of remission or response in Crohn's disease
Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in decrease in CDAI >=50, HBI >=2 or improvement/remission (as defined… compared with placebo (low certainty).
1 finding from 1 review
Induction of remission (CDAI <=150 + decrease of >=50 or as defined by Tvede et al) · patients with Induction of remission or response in Crohn's disease
Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in induction of remission (CDAI <=150 + decrease of >=50 or as defined… compared with placebo (low certainty).
1 finding from 1 review
Mean change in baseline CDAI (Random effects model) · patients with Induction of remission or response in Crohn's disease
1 finding from 1 review
Mean change in baseline CDAI (Fixed effects model) · patients with Induction of remission or response in Crohn's disease
1 finding from 1 review
Maintenance of remission · maintenance of remission in Crohn's disease
Azathioprine or 6‐mercaptopurine may leads to higher maintenance of remission (sensitivity analysis excluding Candy 1995) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine changes withdrawals due to adverse events compared with budesonide (very low certainty).
1 finding from 1 review